These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26130131)

  • 1. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
    Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
    Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies.
    Tembhare PR; Ghogale S; Tauro W; Badrinath Y; Deshpande N; Kedia S; Cherian K; Patkar NV; Chatterjee G; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 May; 94(3):509-519. PubMed ID: 29316178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
    Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
    Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
    Lin P; Owens R; Tricot G; Wilson CS
    Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
    Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Utility of 8-colours multiparameter flow cytometry immunophenotyping of plasma cells for the management of monoclonal gammopathy].
    Gressier M; Chaquin M; Lhermitte L; Asnafi V; Macintyre E; Brouzes C
    Ann Biol Clin (Paris); 2013; 71(3):313-23. PubMed ID: 23747669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.
    Peceliunas V; Janiulioniene A; Matuzeviciene R; Griskevicius L
    Cytometry B Clin Cytom; 2011 Sep; 80(5):318-23. PubMed ID: 21634008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
    Tousková M; Maisnar V; Krejsek J; Kopecký O
    Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
    Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
    Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
    Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
    Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
    Atanackovic D; Panse J; Hildebrandt Y; Jadczak A; Kobold S; Cao Y; Templin J; Meyer S; Reinhard H; Bartels K; Lajmi N; Zander AR; Marx AH; Bokemeyer C; Kröger N
    Haematologica; 2011 Oct; 96(10):1512-20. PubMed ID: 21606160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.